Board of Directors
Kapil Dhingra, MB, BS
Director — Chairman
Kapil Dhingra, MB, BS, is managing member of KAPital Consulting, a healthcare consulting firm he founded in 2008, which provides oncology-related strategic consulting services to biopharmaceutical companies. From 1999̵;2008, he served in positions of increasing responsibility at Hoffmann-La Roche, Inc., including vice president, head, Oncology Disease Biology Leadership team; and head, Oncology Clinical Development. He also worked as a senior clinical research physician at Eli Lilly. Before and during his tenures at both Eli Lilly and Hoffmann-LaRoche, Dr. Dhingra maintained an active academic career first as an assistant professor at M.D. Anderson Cancer Center, then as a clinical associate professor at Indiana University School of Medicine and, most recently, as a clinical affiliate at Memorial Sloan Kettering Cancer Center. Dr. Dhingra also serves on several emerging life science company boards. He received his MB, BS degrees (equivalent to an MD degree in the USA) from the All India Institute of Medical Sciences.
Mr. Boystak has been a director of Exosome Diagnostics since May 2009 and serves as Chairman of the Audit Committee. He is President and CEO of Brightwaters Capital, LLC, a venture capital firm based in Los Angeles that focuses on life sciences, medical devices, diagnostics, health care and nanotechnology. He also serves as Managing Director and CEO of Hudson | Brightwaters, a boutique merchant bank. Previously, Boystak spent more than 20 years as an investment banker with several major Wall Street firms and completed over $15 billion of financing and advisory transactions. He most recently served as founding Managing Director of the Global Life Science Group at Jefferies & Co. He is currently Co-Founder and Chairman of NanoPacific Holdings, Inc. and is Co-Founder and Managing Member of Bruin Biometrics, LLC. He also serves on the Health Advisory Board at The Johns Hopkins Bloomberg School of Public Health and is a member of the UCLA Foundation Board of Governors. Mr. Boystak received his B.A. from Boston University and Master of Health Science from The Johns Hopkins Bloomberg School of Public Health.
Peter Johann, PhD
Dr. Johann is a Managing General Partner of NGN Capital. He joined NGN Capital from Boehringer Ingelheim, where he was the Division Head of Corporate Development responsible for strategic planning, strategic projects, M&A, business development and licensing. Prior to this, Mr. Johann has served at F. Hoffmann-La Roche as Global Business Leader where he led global business teams and was responsible for global marketing of oncology products as well as evaluation of pipeline products from internal and external sources. Dr. Johann joined Roche from Boehringer Mannheim, where he was Head of Business Development and Marketing Molecular Medicine. Dr. Johann obtained his PhD from the Technical University Munich. Dr. Johann holds Board seats with Cerapedics (Observer), Exosome, Horizon Pharma (after the Nitec merger), Micromet, Resverlogix, Vivaldi Biosciences and held Board and Observer seats at Jerini and Santhera respectively.
Chief Executive Officer
Mr. McLain has a proven track record of accomplishment in building life science companies and generating significant shareholder value. Most recently, he was the CEO of Vermillion, a medical diagnostics company focused on women's health. While there, he led a strategic transformation of the company increasing its market capitalization fivefold to over $100 million. Prior to joining Vermillion, he was the CEO of start-up Claro Scientific, a diagnostics company with a novel optics-based platform technology. Previously he was chairman, CEO and president of Nabi Biopharmaceuticals where he led the evolution of a plasma supply based business into a fully integrated biopharmaceutical company. Over his career, he has raised over $300 million in new capital and structured successful commercial alliances, joint ventures and research collaborations. Mr. McLain earned his B.A. at the College of the Holy Cross, Worcester, Mass., and his M.B.A. from the University of Rochester, Rochester NY.
Geert-Jan Mulder, MD
Geert-Jan Mulder, M.D., co-founded Forbion in 2006 and currently serves on the Board of several Forbion portfolio companies. In addition, Geert-Jan led the firm’s successful investment in bluebirdbio (NASDAQ: BLUE), which went public in 2013, where he supported the company in clinical development and served as the chairman for several years. Other investments include Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006 where he was part of the AMPYRA® (dalfampridine) board panel to evaluate a new clinical endpoint in multiple sclerosis; PanGenetics B.V., which sold to Abbott, where he led the Series B financing round; and Transave, where he supported the company's clinical development for ARIKAYCE® (liposomal amikacin for inhalation) partly as interim CMO and also served on the Board of Directors until the merger with Insmed (NASDAQ:INSM) in 2010.
Prior to joining ABN AMRO Capital Life Sciences (Forbion's predecessor) in 2001, Geert-Jan received his medical degree from the University of Utrecht (NL) and spent two years as a clinician in Obstetrics and Gynecology at the University Medical Center of Utrecht (UMC). He then joined Searle (now Pfizer) working in the field of arthritis and pain, involved in clinical development as well as in the European Advocacy Development for the pre-launch of Celebrex®. After transitioning to Byk Gulden (now Takeda), he became Clinical Research Manager, where his department was responsible for the design and execution of numerous early and late stage clinical trials that formed the basis for two global product registrations, i.e., Daxas® and Alvesco® in the field of Respiratory Medicine (asthma and COPD). He was a member of the Global Medical Marketing group of their Respiratory Franchise and was involved in the line extension program for Pantozol®.
Mr. Slattery joined the Exosome Diagnostics Board of Directors in June 2013. He is currently the Executive Vice President and Chief Financial Officer at Baxano Surgical, Inc., after serving as a member of its Board of Directors and Chairman of its Audit Committee from November 2007 until April 2010. He also serves on the Board of Directors of CVRx, Inc. a privately held company developing implantable technology for the treatment of hypertension and heart disease, and served as a Director, Chairman of the Audit Committee and member of the Nominating & Governance Committee of Micromet, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of antibodies for the treatment of cancer, inflammation and autoimmune diseases, which was acquired by Amgen in March, 2012 for $1.2 billion. Mr. Slattery was Chief Financial Officer and Senior Vice President, Digene Corporation, a molecular diagnostics company that developed and marketed the first FDA-approved test for Human Papillomavirus that was acquired by Qiagen, N.V. in 2007 for $1.6 billion. Mr. Slattery received a B.S. degree in Accountancy from Bentley University and is a Certified Public Accountant.
Steven L. Soignet, MD
Dr. Soignet is a co-founder of Arcus Ventures. In 2003, he became a venture partner of Cross Atlantic Partners, a healthcare and biotechnology venture capital fund. Dr. Soignet held a faculty appointment in the Developmental Chemotherapy Service at Memorial Sloan-Kettering Cancer Center, and in the Department of Medicine at Cornell University Medical Center. His primary research focus was in early phase clinical drug development in both hematological and solid tumors. He was a lead investigator of a Pilot and a large USA Multicenter Trial that led to FDA and European approval of arsenic trioxide for the treatment of relapsed acute promyelocytic leukemia. Dr. Soignet's research has been published in the New England Journal of Medicine, Leukemia, Blood, Journal of Clinical Oncology and Clinical Cancer Research. Dr. Soignet received his B.S. from the University of New Orleans, and his M.D. (AOA, honors) from Louisiana State University School of Medicine. His fellowship training was in medical oncology/hematology at Memorial Sloan-Kettering Cancer Center.